Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 1081-1086

  Pagano, Claudio ^a   Soardo, Giorgio ^b   Pilon, Catia ^a   Milocco, Carla ^b   Basan, Lorenza ^b   Milan, Gabriella ^a   Donnini, Debora ^b   Faggian, Diego ^c   Mussap, Michele ^c   Plebani, Mario ^c   Avellini, Claudio ^b   Federspil, Giovanni ^a   Sechi, Leonardo A ^b   Vettor, Roberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMINOTRANSFERASE; C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; MESSENGER RNA; RESISTIN;

ADIPOSE TISSUE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER DISEASE; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPIDS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OBESITY; REFERENCE VALUES; RESISTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

EID: 33644825288     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1056     Document Type: Article

References (52)

1. Angulo P 2002 Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
2. American Gastroenterology Association 2002 Medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123:1702-1704
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M 2003 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923
4. Tsao TS, Lodish HF, Fruebis J 2002 ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213-221
5. Diez JJ, Iglesias P 2003 The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293-300
6. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312
7. Guerre-Millo M 2004 Adipose tissue and adipokines: for better or worse. Diabetes Metab 30:13-19
8. Pittas AG, Joseph NA, Greenberg AS 2004 Adipocytokines and insulin resistance. J Clin Endocr Metab 89:447-452
9. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM 2004 Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 114:224-231
10. Steppan CM, Lazar MA 2004 The current biology of resistin. J Intern Med 255:439-447
11. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L 2004 Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114:232-239
12. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A 2004 Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450-2457
13. Dzielinska Z, Januszewicz A, Wiecek A, Demkow M, Makowiecka-Ciesla M, Prejbisz A, Kadziela J, Mielniczuk R, Florczak E, Janas J, Januszewicz M, Ruzyllo W 2003 Decreased plasma concentration of a novel anti-inflammatory protein-adiponectin-in hypertensive men with coronary artery disease. Thromb Res 110:365-369
14. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R 2004 Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415-419
15. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A 2005 Resistin, an adipokine with potent proinflammatory properties. J Immunol 174:5789-5795
16. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ 2003 The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100
17. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
18. Despres JP 2003 Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes Relat Metab Disord 27(Suppl 3):S22-S24
19. Sjoholm A, Nystrom T 2005 Endothelial inflammation in insulin resistance. Lancet 365:610-612
20. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD 1991 Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 43:26-31
21. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR 1999 Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474
22. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E 2001 Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47:444-450
23. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R 2005 Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113-118
24. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, DE Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G 2005 Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498-3504
25. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M 2004 Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339:57-63
26. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV 2003 Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88:5452-5455
27. Volarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA 2004 High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53:1279-1284
28. Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D 2004 Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 81:361-366
29. Silha JV, Murphy LJ 2004 Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 89:1977-1978
30. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS 2004 Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89:150-156
31. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR 2004 Relationship between serum resistin concentrations and insulin resistance in non obese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89:1844-1848
32. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS 2003 Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848-4856
33. Zhang JL, Qin YW, Zheng X, Qiu JL, Zou DJ 2003 Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 20:828-831
34. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ 2003 Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 149:331-335
35. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA 2004 Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28:783-789
36. Stejskal D, Adamovska S, Bartek J, Jurakova R, Proskova J 2003 Resistin: concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147:63-69
37. Pagano C, Marin O, Calcagno C, Schiappelli C, Pilon C, Milan G, Bertelli M, Fanin E, Andrighetto G, Federspil G, Vettor R 2005 Increased serum resistin in adults with Prader-Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 90:4335-4340
38. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G 2003 A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52:1611-1618
39. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA 2004 Regulation of fasted blood glucose by resistin. Science 303:1195-1198
40. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA 2004 Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937-1941
41. Rajala MW, Obici S, Scherer PE, Rossetti L 2003 Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 111:225-230
42. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H, Rhee EJ, Lee WY, Kim SW 2004 Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 19:694-698
43. Behre CJ, Fagerberg B, Hulten LM, Hulthe J 2005 The reciprocal association of adipocytokines with insulin resistance and C-reactive protein in clinically healthy men. Metabolism 54:439-444
44. Kazumi T, Kawaguchi A, Hirano T, Yoshino G 2003 C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 52:1113-1116
45. Festa A, D'Agostino Jr R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM 2001 The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 25:1407-1415
46. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, Vettor R 2002 Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10:1095-1103
47. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ 2003 Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413-419
48. Chitturi S, Farrell GC 2001 Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21:27-41
49. Diehl AM 2002 Nonalcoholic steatosis and steatohepatitis. IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol 282:G1-G5
50. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY, Park HJ, Shin HD, Park KS 2004 Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 47:1337-1338
51. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L 2004 Disulfide-dependent multimeric assembly of resistin family hormones. Science 304:1154-1158
52. Nohira T, Nagao K, Kameyama K, Nakai H, Fukumine N, Okabe K, Kitano S, Hisatomi H 2004 Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue. Eur J Endocrinol 151:151-154